Sorafenib inhibits the proliferation of human oral cancer TCA8113 cells through the activation of p38MAPK

VernacularTitle:索拉菲尼通过活化p38MAPK抑制人口腔癌TCA8113细胞增殖
Author: Shuqing GE ; Guizhi JIA ; Hongliang DAI ; Yue WANG ; Chunguang LIANG
Keywords: Sorafenib; TCA8113; Proliferation; p38MAPK
From: Journal of Practical Stomatology 2017;33(1):105-108
CountryChina
Language:Chinese
Abstract: Objective:To investigate the effect of sorafenib on the proliferation of human oral cancer TCA8113 cells and to explore the underlying mechanisms.Methods:Mter treated with sorafenib at 2.5,5,10,20 μg/ml respectively for48 h,TCA8113 cell proliferation was examined by MTT and colony formation assay.Western blotting was employed to examine the p38MAPK expression in the cells.TCA8113 cells were pretreated with 10 μmol/L of SB203580 (a specific inhibitor of p38MAPK) for 30 min,and then by different concentrations of sorafenib for 48 h,cell proliferation was tested by MTT assay.Results:Sorafenib significantly inhibited the proliferation of TCA8113 cells in a concentration dependent fashion.Sorafenib also remarkably promoted the activation of p38MAPK of the cells.SB203580 significantly alleviated soiafenib induced TCA8113 cell viability decrease.Conclusion:Sorafenib can inhibit the proliferation of TCA8113 cells,which may be related to the activation of p38MAPK.